摘要
目的:初步探讨III期非小细胞肺癌(NSCLC)患者中p53mRNA表达与新辅助化疗敏感性及预后的关系。方法:选取30例行新辅助化疗的III期NSCLC患者,应用RTPCR法分别检测肿瘤与同肺叶正常组织p53mRNA的表达,随访患者生存情况。结果:①肿瘤组织中p53mRNA表达阳性17例(56.7%),正常组织中3例(10%),二者有统计学差异(P<0.05);②所有患者中位生存时间为18.9个月。肿瘤组织中p53mRNA阳性者中位生存时间13.1个月,阴性者32.0个月,二者有统计学差别(P<0.05)。结论:III期NSCLC患者正常组织中p53mRNA呈低表达,肿瘤组织中则呈高表达。p53mRNA表达可预测新辅助化疗的疗效。
Objective： To investigate the relationship of p53mRNA expression with sensitivity and prognosis of neo-adjuvant chemotherapy for Ⅲ non-small cell lung cancer （NSCLC）. Methods： The expression of p53mRNA in tumor tissues and normal tissues of thirty patients with Ⅲ NSCLC who received neo-adjuvant chemotherapy was determined by RT-PCR, and their survival time was surveyed. Results： ① p53 mRNA expressed positively in 17 tumor tissues （56.7%, 17/30）, and 3 normal tissues （10.0%, 3/30） with a significant difference P〈0.05）; ② The median life time was significantly different between the patients with positive tumor tissues （13.1 months） and those with negative tissues （32 months）. Conclusions： ③ The rate of p53mRNA expression is higher in tumor tissues than in normal tissues. ④ The p53mRNA expression can be used to predict the effect of neo-adjuvant chemotherapy.
出处
《山东大学学报（医学版）》
CAS
北大核心
2005年第10期952-955,共4页
Journal of Shandong University:Health Sciences
基金
山东省卫生厅青年科学研究基金(CA2DBA3)。
关键词
蛋白质
p53
逆转录聚合酶链反应
癌
非小细胞肺
新辅助化疗
Protein, p53
Reverse transcription-polymerase chain reaction
Carcinoma, non-smallcell lung
Neoadjuvant chemotherapy
